
Co-Diagnostics CODX
Quarterly report 2025-Q3
added 11-13-2025
Co-Diagnostics Accounts Receivables 2011-2026 | CODX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Co-Diagnostics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 304 K | 3.45 M | 20.8 M | 12.1 M | 131 K | 13.4 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.8 M | 13.4 K | 6.15 M |
Quarterly Accounts Receivables Co-Diagnostics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.9 K | 211 K | 136 K | 133 K | 178 K | 552 K | - | 304 K | 807 K | 1.1 M | 2.7 M | 3.45 M | 7.96 M | 12.3 M | 21.7 M | 20.8 M | 14.6 M | 12.8 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 131 K | 131 K | 131 K | 131 K | 13.4 K | 13.4 K | 13.4 K | 13.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.7 M | 13.4 K | 5.36 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 29.0 | -3.07 % | $ 316 M | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
4.75 M | $ 1.14 | -2.16 % | $ 1.45 M | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
Danaher Corporation
DHR
|
3.54 B | $ 210.56 | -0.33 % | $ 154 B | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 29.41 | -6.17 % | $ 817 M | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 202.21 | -0.11 % | $ 22.4 B | ||
|
DexCom
DXCM
|
1.22 B | $ 73.08 | 1.11 % | $ 28.5 B | ||
|
DarioHealth Corp.
DRIO
|
3.16 M | $ 11.75 | 2.8 % | $ 333 M | ||
|
CareDx, Inc
CDNA
|
51.1 M | $ 18.83 | -5.23 % | $ 1.01 B | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Illumina
ILMN
|
735 M | $ 117.53 | -2.06 % | $ 18.7 B | ||
|
Fulgent Genetics
FLGT
|
69 M | $ 23.18 | -0.39 % | $ 701 M | ||
|
Exact Sciences Corporation
EXAS
|
299 M | $ 103.45 | 0.15 % | $ 19.5 B | ||
|
Lantheus Holdings
LNTH
|
321 M | $ 74.31 | 1.54 % | $ 5.14 B | ||
|
Guardant Health
GH
|
138 M | $ 103.36 | -2.84 % | $ 13 B | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
1.34 B | $ 99.61 | 1.22 % | $ 8.22 B | ||
|
Interpace Biosciences
IDXG
|
8.54 M | $ 1.85 | 2.78 % | $ 8.12 M | ||
|
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B | ||
|
Charles River Laboratories International
CRL
|
709 M | $ 169.68 | 3.11 % | $ 8.41 B | ||
|
IDEXX Laboratories
IDXX
|
474 M | $ 635.6 | 0.77 % | $ 52.4 B | ||
|
IQVIA Holdings
IQV
|
3.4 B | $ 166.19 | -1.87 % | $ 28.6 B | ||
|
Biodesix
BDSX
|
8.6 M | $ 13.26 | 4.0 % | $ 1.72 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.94 B | $ 283.38 | 0.32 % | $ 23.8 B | ||
|
Biomerica
BMRA
|
731 K | $ 2.17 | -2.25 % | $ 4.98 M | ||
|
Bioventus
BVS
|
123 M | $ 8.57 | -0.06 % | $ 537 M | ||
|
Medpace Holdings
MEDP
|
402 M | $ 452.99 | 1.47 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | ||
|
National Research Corporation
NRC
|
12.4 M | $ 13.65 | 9.64 % | $ 335 M | ||
|
Mettler-Toledo International
MTD
|
778 M | $ 1 378.44 | 0.14 % | $ 28.4 B |